Corvus Pharmaceuticals, Inc. 4
4 · Corvus Pharmaceuticals, Inc. · Filed Mar 29, 2016
Insider Transaction Report
Form 4
LEA LEIV
Chief Financial Officer
Transactions
- Conversion
Common Stock, $0.0001 par value
2016-03-29+42,608→ 199,253 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2016-03-29−42,608→ 0 total(indirect: By Trust)→ Common Stock (42,608 underlying)
Footnotes (4)
- [F1]The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.
- [F2]A portion of these shares is subject to a right of repurchase held by the Issuer.
- [F3]These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.
- [F4]The expiration date is not relevant to the conversion of these securities.